CardioGenics Holdings Inc (CGNH)
USD 0.0
(99.0%)
USD 0.0
(99.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2015 | 1.79 Million USD | 25.96% |
| 2014 | 1.42 Million USD | -2.73% |
| 2013 | 1.46 Million USD | 64.83% |
| 2012 | 888.76 Thousand USD | 99.71% |
| 2011 | 445.03 Thousand USD | -23.29% |
| 2010 | 580.18 Thousand USD | -37.15% |
| 2009 | 923.14 Thousand USD | 170.75% |
| 2008 | 340.95 Thousand USD | -97.69% |
| 2007 | 14.77 Million USD | 191.16% |
| 2006 | 5.07 Million USD | 133.87% |
| 2005 | 2.16 Million USD | 1972.2% |
| 2004 | 104.69 Thousand USD | -82.53% |
| 2003 | 599.46 Thousand USD | -56.99% |
| 2002 | 1.39 Million USD | 214.03% |
| 2001 | 443.86 Thousand USD | -81.03% |
| 2000 | 2.34 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2016 Q1 | 2.34 Million USD | 30.64% |
| 2015 Q1 | 1.82 Million USD | 27.78% |
| 2015 Q4 | 1.79 Million USD | -3.93% |
| 2015 FY | 1.79 Million USD | 25.96% |
| 2015 Q3 | 1.86 Million USD | 20.67% |
| 2015 Q2 | 1.54 Million USD | -14.97% |
| 2014 Q4 | 1.42 Million USD | -29.61% |
| 2014 FY | 1.42 Million USD | -2.73% |
| 2014 Q1 | 1.36 Million USD | -7.12% |
| 2014 Q2 | 1.49 Million USD | 9.65% |
| 2014 Q3 | 2.02 Million USD | 35.69% |
| 2013 FY | 1.46 Million USD | 64.83% |
| 2013 Q2 | 1.36 Million USD | 15.85% |
| 2013 Q4 | 1.46 Million USD | 28.04% |
| 2013 Q3 | 1.14 Million USD | -16.21% |
| 2013 Q1 | 1.17 Million USD | 32.62% |
| 2012 Q4 | 888.76 Thousand USD | -2.98% |
| 2012 Q3 | 916.05 Thousand USD | 0.61% |
| 2012 FY | 888.76 Thousand USD | 99.71% |
| 2012 Q1 | 600.51 Thousand USD | 34.94% |
| 2012 Q2 | 910.48 Thousand USD | 51.62% |
| 2011 FY | 445.03 Thousand USD | -23.29% |
| 2011 Q4 | 445.03 Thousand USD | -80.19% |
| 2011 Q3 | 2.24 Million USD | 366.04% |
| 2011 Q2 | 481.97 Thousand USD | 7.2% |
| 2011 Q1 | 449.61 Thousand USD | -22.5% |
| 2010 FY | 580.18 Thousand USD | -37.15% |
| 2010 Q3 | 515.87 Thousand USD | 8.27% |
| 2010 Q4 | 580.18 Thousand USD | 12.47% |
| 2010 Q1 | 778.24 Thousand USD | -15.7% |
| 2010 Q2 | 476.49 Thousand USD | -38.77% |
| 2009 Q1 | 438 Thousand USD | 23.69% |
| 2009 FY | 923.14 Thousand USD | 170.75% |
| 2009 Q4 | 923.14 Thousand USD | -93.0% |
| 2009 Q3 | 13.19 Million USD | 3219.58% |
| 2009 Q2 | 397.43 Thousand USD | -9.26% |
| 2008 Q2 | 486.1 Thousand USD | 13.8% |
| 2008 FY | 340.95 Thousand USD | -97.69% |
| 2008 Q4 | 354.11 Thousand USD | 3.86% |
| 2008 Q3 | 340.95 Thousand USD | -29.86% |
| 2008 Q1 | 427.16 Thousand USD | -96.19% |
| 2007 Q1 | 7.66 Million USD | 55.87% |
| 2007 Q2 | 8.55 Million USD | 11.56% |
| 2007 Q4 | 11.2 Million USD | -24.16% |
| 2007 Q3 | 14.77 Million USD | 72.71% |
| 2007 FY | 14.77 Million USD | 191.16% |
| 2006 FY | 5.07 Million USD | 133.87% |
| 2006 Q4 | 4.91 Million USD | -3.05% |
| 2006 Q1 | 2.87 Million USD | 18.72% |
| 2006 Q2 | 3.51 Million USD | 22.45% |
| 2006 Q3 | 5.07 Million USD | 44.2% |
| 2005 Q4 | 2.42 Million USD | 11.57% |
| 2005 FY | 2.16 Million USD | 1972.2% |
| 2005 Q2 | 2.06 Million USD | 260.43% |
| 2005 Q3 | 2.16 Million USD | 4.86% |
| 2005 Q1 | 574.04 Thousand USD | 427.59% |
| 2004 FY | 104.69 Thousand USD | -82.53% |
| 2004 Q4 | 108.8 Thousand USD | 3.92% |
| 2004 Q3 | 104.69 Thousand USD | -0.08% |
| 2004 Q2 | 104.78 Thousand USD | -82.29% |
| 2004 Q1 | 591.52 Thousand USD | 10.64% |
| 2003 Q3 | 599.46 Thousand USD | 2.25% |
| 2003 Q4 | 534.64 Thousand USD | -10.81% |
| 2003 Q2 | 586.27 Thousand USD | -7.92% |
| 2003 FY | 599.46 Thousand USD | -56.99% |
| 2003 Q1 | 636.67 Thousand USD | -40.31% |
| 2002 Q4 | 1.06 Million USD | -23.47% |
| 2002 Q1 | 595.11 Thousand USD | -16.55% |
| 2002 Q2 | 919.3 Thousand USD | 54.48% |
| 2002 Q3 | 1.39 Million USD | 51.62% |
| 2002 FY | 1.39 Million USD | 214.03% |
| 2001 Q2 | 183.29 Thousand USD | -94.04% |
| 2001 FY | 443.86 Thousand USD | -81.03% |
| 2001 Q1 | 3.07 Million USD | -3.03% |
| 2001 Q4 | 713.12 Thousand USD | 60.66% |
| 2001 Q3 | 443.86 Thousand USD | 142.17% |
| 2000 Q3 | 2.34 Million USD | 665.81% |
| 2000 Q2 | 305.58 Thousand USD | 48.12% |
| 2000 Q1 | 206.3 Thousand USD | 0.0% |
| 2000 FY | 2.34 Million USD | 0.0% |
| 2000 Q4 | 3.16 Million USD | 35.44% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | 50.252% |
| Arrayit Corporation | 7.49 Million USD | 76.057% |
| Atlantic International Corp. | 3.82 Million USD | 53.118% |
| Biocept, Inc. | 22.01 Million USD | 91.846% |
| Bioqual, Inc. | 18.93 Million USD | 90.522% |
| DermTech, Inc. | 64.75 Million USD | 97.228% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 99.756% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 85.508% |
| iMD Companies, Inc. | 1.67 Million USD | -7.21% |
| IDenta Corp. | 1.01 Million USD | -77.161% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 93.625% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -502.43% |
| InVitro International | 78.99 Thousand USD | -2172.342% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 90.902% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -1288.217% |
| Medical Imaging Corp. | 9.51 Million USD | 81.14% |
| NovelStem International Corp. | 4.2 Million USD | 57.326% |
| Optigenex Inc. | 9.57 Million USD | 81.245% |
| PharmChem, Inc. | 558.64 Thousand USD | -221.298% |
| Proteome Sciences plc | 18.48 Million USD | 90.292% |
| Response Genetics, Inc | 15.86 Million USD | 88.688% |
| Rennova Health, Inc. | 49.66 Million USD | 96.386% |
| RushNet, Inc. | 6.23 Million USD | 71.231% |
| ScreenPro Security Inc. | 1.6 Million USD | -12.142% |
| Stella Diagnostics Inc. | 18 Million USD | 90.031% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | 78.121% |
| Todos Medical Ltd. | 50.15 Million USD | 96.421% |